Black Diamond Therapeutics, Inc. Common Stock
BDTXBlack Diamond Therapeutics, Inc. (BDTX) is a biotechnology company focused on developing precision oncology medicines. It utilizes its unique oncology master key platform to identify and target specific genetic mutations in cancer, aiming to deliver personalized treatment options for patients with difficult-to-treat tumors.
Company News
Black Diamond Therapeutics (BDTX) stock climbed on Tuesday following the announcement of encouraging Phase 2 data for silevertinib in frontline non-small cell lung cancer patients with EGFR non-classical mutations. The company beat Q1 earnings estimates with a loss of 16 cents per share versus expected 18 cents, and holds $118.3 million in cash e...
Black Diamond Therapeutics announced positive Phase 2 results for silevertinib, its brain-penetrant EGFR inhibitor, in frontline NSCLC patients with EGFR non-classical mutations. The trial showed a preliminary median progression-free survival of 15.2 months, 60% overall response rate, and robust CNS activity with 86% CNS objective response rate. ...
Black Diamond Therapeutics reported a narrower net loss in Q2 2025, with improved operational efficiency and focus on silevertinib clinical development. The company completed Phase 2 trial enrollment and maintains a cash runway through Q4 2027.
Clarus reported Q2 2025 earnings with mixed results, narrowly beating analyst expectations on revenue and adjusted net loss per share, but experiencing revenue decline and ongoing profitability challenges.
Servier and Black Diamond Therapeutics have announced a global licensing agreement for BDTX-4933, a targeted oncology therapy in Phase 1 development. Servier will lead the development and commercialization of the therapy, with Black Diamond receiving an upfront payment and potential milestone and royalty payments.
